Search Results - "Lin, Hugh"

Glaucoma Screening Using Relative Afferent Pupillary Defect by Charalel, Resmi A, Lin, Hugh S, Singh, Kuldev

“…PURPOSE:To assess the relative afferent pupillary defect (RAPD) by swinging flashlight as a potentially useful screening test for glaucomatous optic…”
Get full text

YOSEMITE and RHINE by Eter, Nicole, Singh, Rishi P., Abreu, Francis, Asik, Kemal, Basu, Karen, Baumal, Caroline, Chang, Andrew, Csaky, Karl G., Haskova, Zdenka, Lin, Hugh, Ruiz, Carlos Quezada, Ruamviboonsuk, Paisan, Silverman, David, Wykoff, Charles C., Willis, Jeffrey R.

“…Faricimab is a novel anti–angiopoietin-2 and anti–vascular endothelial growth factor (VEGF) bispecific antibody with high affinities and specificities for both…”
Get full text

TENAYA and LUCERNE by Khanani, Arshad M., Guymer, Robyn H., Basu, Karen, Boston, Heather, Heier, Jeffrey S., Korobelnik, Jean-François, Kotecha, Aachal, Lin, Hugh, Silverman, David, Swaminathan, Balakumar, Willis, Jeffrey R., Yoon, Young Hee, Quezada-Ruiz, Carlos

“…To describe the design and rationale of the phase 3 TENAYA (ClinicalTrials.gov identifier, NCT03823287) and LUCERNE (ClinicalTrials.gov identifier,…”
Get full text

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials by Abreu, Francis, Adamis, Anthony P, Eichenbaum, David A, Haskova, Zdenka, Lin, Hugh, Loewenstein, Anat, Mohan, Shaun, Wells, John A, Willis, Jeffrey R, Aaberg, Thomas, Alam, Suhail, Amini, Payam, Antoszyk, Andrew, Asaria, Riaz, Avila, Marcos, Awh, Carl C, Bafalluy, Joaquin, Bator, Gyorgy, Burgess, Stuart, Calzada, Jorge, Campochiaro, Peter, Chang, Jonathan, Chaudhry, Nauman, Chee, Caroline, Chittum, Mark, Chow, David, Cornut, Pierre Loic, Eldem, Bora, Ernest, Jan, Feiner, Leonard, Fernandez, Carlos, Ferrone, Philip, Figueroa, Marta, Fine, Howard, Foxman, Scott, Fung, Nicholas, Garcia-Layana, Alfredo, Gawecki, Maciej, Ghanchi, Faruque, Goldberg, Roger, Gonzalez, Victor, Higgins, Patrick, Ho, Allen, Holekamp, Nancy, Hsu, Jason, Ikeda, Yasuhiro, Jhaveri, Chirag, Kapoor, Kapil, Kerenyi, Agnes, Khanani, Arshad, Kitano, Shigehiko, Korobelnik, Jean Francois, Lalonde, Laurent, Larsen, Michael, Laugesen, Caroline, Lebreton, Olivier, Lee, Seong, Liu, Mimi, Lorenz, Katrin, Lozano Rechy, David, Margherio, Alan, Menon, Geeta, Michalska-Malecka, Katarzyna, Morori-Katz, Haia, Newell, Charles, Nicolo, Massimo, Nielsen, Jared, Osher, James, Papp, Andras, Pearce, Ian, Pertile, Grazia, Raskauskas, Paul, Razavi, Hessam, Rosenblatt, Brett, Sandner, Dirk, Sermet, Figen, Shah, Sandeep, Sharma, Sumit, Spital, Georg, Stern, Jeffrey, Stone, Cameron, Stone, Amy, Sun, Jennifer, Szalczer, Lajos, Szecsko, Timea, Tadayoni, Ramin, Talks, James, Tanabe, Teruyo, Torti, Robert, Tosheva Guneva, Daniela, Varma, Deepali, Vassileva, Petja, Weber, Pamela, Wells, John A, Williams, Thomas, Wykoff, Charles C, Yilmaz, Gursel, Yiu, Glenn, Yurieva, Tatiana, Zatorska, Barbara

“…To reduce treatment burden and optimise patient outcomes in diabetic macular oedema, we present 1-year results from two phase 3 trials of faricimab, a novel…”
Get full text

Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials by Holekamp, Nancy, Wykoff, Charles C, Schmitz-Valckenberg, Steffen, Monés, Jordi, Souied, Eric H, Lin, Hugh, Rabena, Melvin D, Cantrell, Ronald A, Henry, Erin C, Tang, Fan, Swaminathan, Balakumar, Martin, Jillian, Ferrara, Daniela, Staurenghi, Giovanni

“…To better characterize visual function decline and geographic atrophy (GA) progression secondary to age-related macular degeneration (AMD). Proxima A…”
Get full text

86-OR: Primary Results from Two Phase 3 Trials of Faricimab for Diabetic Macular Edema (DME): YOSEMITE and RHINE by HU, ALLEN, WILLIS, JEFFREY R., HASKOVA, ZDENKA, SILVERMAN, DAVID, IVES, JANE, BASU, KAREN, LIN, HUGH

“…The leading cause of vision loss in people with diabetic retinopathy (DR) is DME. Intravitreal anti-VEGF therapy is the standard of care for DME; however,…”
Get full text

Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: A multicenter, double-masked, randomized 30-day study by Lievens, Christopher, Berdy, Gregg, Douglass, David, Montaquila, Stephen, Lin, Hugh, Simmons, Peter, Carlisle-Wilcox, Cindy, Vehige, Joseph, Haque, Sameena

“…•Carboxymethylcellulose (CMC) 1.0%, with increased molecular weight, enhances viscosity and efficacy of artificial tears.•The inclusion of glycerin (GLY) and…”
Get full text

TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2 by Khanani, Arshad M, Kotecha, Aachal, Chang, Andrew, Chen, Shih-Jen, Chen, Youxin, Guymer, Robyn, Heier, Jeffrey S, Holz, Frank G, Iida, Tomohiro, Ives, Jane A, Lim, Jennifer I, Lin, Hugh, Michels, Stephan, Quezada Ruiz, Carlos, Schmidt-Erfurth, Ursula, Silverman, David, Singh, Rishi, Swaminathan, Balakumar, Willis, Jeffrey R, Tadayoni, Ramin

“…To evaluate 2-year efficacy, durability, and safety of the bispecific antibody faricimab, which inhibits both angiopoietin-2 and VEGF-A.PURPOSETo evaluate…”
Get full text

Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials by Wong, Tien Y, Haskova, Zdenka, Asik, Kemal, Baumal, Caroline R, Csaky, Karl G, Eter, Nicole, Ives, Jane A, Jaffe, Glenn J, Korobelnik, Jean-François, Lin, Hugh, Murata, Toshinori, Ruamviboonsuk, Paisan, Schlottmann, Patricio G, Seres, András I, Silverman, David, Sun, Xiaodong, Tang, Yannan, Wells, John A, Yoon, Young Hee, Wykoff, Charles C

“…To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A pathway inhibition with…”
Get full text

47-OR: Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: Two-Year Results from the Phase 3 YOSEMITE and RHINE Trials by DANZIG, CARL J., WELLS, JOHN A., EICHENBAUM, DAVID, LIM, JENNIFER I., ASIK, KEMAL, HASKOVA, ZDENKA, MOHAN, SHAUN, SILVERMAN, DAVID, TANG, YANNAN, LIN, HUGH

“…Diabetic macular edema (DME) is a major cause of vision loss for people with diabetes. Intravitreal anti-vascular endothelial growth factor (VEGF) therapy is…”
Get full text

Faricimab Treat-and-Extend for Diabetic Macular Edema: 2-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials by Wong, Tien Y, Haskova, Zdenka, Asik, Kemal, Baumal, Caroline R, Csaky, Karl G, Eter, Nicole, Ives, Jane A, Jaffe, Glenn J, Korobelnik, Jean-François, Lin, Hugh, Murata, Toshinori, Ruamviboonsuk, Paisan, Schlottmann, Patricio G, Seres, András I, Silverman, David, Sun, Xiaodong, Tang, Yannan, Wells, John A, Yoon, Young Hee, Wykoff, Charles C

“…To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2/vascular endothelial growth factor (VEGF)-A pathway inhibition with intravitreal…”
Get full text

Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials by Takahashi, Kanji, Cheung, Chui Ming Gemmy, Iida, Tomohiro, Lai, Timothy Y. Y., Ohji, Masahito, Yanagi, Yasuo, Kawano, Mika, Ohsawa, Shino, Suzuki, Tomoyuki, Kotecha, Aachal, Lin, Hugh, Patel, Vaibhavi, Swaminathan, Balakumar, Lee, Won Ki

“…Purpose To evaluate 1-year efficacy, durability, and safety of faricimab among patients from Asian countries in the TENAYA/LUCERNE trials of neovascular…”
Get full text

Microperimetry for geographic atrophy secondary to age-related macular degeneration by Csaky, Karl G., Patel, Praveen J., Sepah, Yasir J., Birch, David G., Do, Diana V., Ip, Michael S., Guymer, Robyn H., Luu, Chi D., Gune, Shamika, Lin, Hugh, Ferrara, Daniela

“…Geographic atrophy (GA) is a progressive, advanced form of age-related macular degeneration leading to visual function impairment and irreversible vision loss…”
Get full text

TENAYA and LUCERNE by Chen, Youxin, Heier, Jeffrey S., Lin, Hugh, Quezada Ruiz, Carlos, Swaminathan, Balakumar, Abbey, Ashkan, Abdulaeva, Elmira, Abraham, Prema, Alfaro, Virgil, Altay, Lebriz, Amini, Payam, Aradi, Etelka, Arias, Luis, Arnold, Jennifer, Astakhov, Sergei, Banerjee, Sanjiv, Becker, Matthias, Belfort, Rubens, Bridges, William Z., Brown, David M., Cameron, Stone, Carlson, John, Chan, Clement, Chang, Andrew, Chee, Caroline, Cheek, Andrew, Chen, San-Ni, Chexal, Saradha, Connolly, Brian, Couvillion, Stephen, Daskalov, Vesselin, Devin, Francois, Dollin, Michael, Dolz, Rosa, Dreyer, Richard, Dugel, Pravin, Eichenbaum, David, Engstrom, Robert, Eter, Nicole, Ferrone, Philip, Figueroa, Marta, Fraser-Bell, Samantha, Fung, Nicholas, Gale, Richard, Garcia-Layana, Alfredo, Glaser, David, Gupta, Sunil, Hampton, Robert, Heier, Jeffrey, Higgins, Patrick, Howard, James, Hu, Allen, Huddleston, Stephen, Ito, Yasuo, Itty, Sujit, Javid, Cameron, Khanani, Arshad, Kodjikian, Laurent, Koizumi, Hideki, Lalonde, Laurent, Lee, Won Ki, London, Nikolas, Mahmood, Sajjad, Matsubara, Hisashi, Mentes, Jale, Mitamura, Yoshinori, Mones, Jordi, Lobo, Rodrigo Montemayor, Nardi, Marco, Narendran, Niro, Noda, Kousuke, Nowinska, Anna, Parke, D. Wilk, Petkova, Iva, Pieramici, Dante, Pozdeyeva, Nadezhda, Raczynska, Dorota, Romanowska-Dixon, Bożena, Rosenblatt, Irit, Sacu, Stefan, Sandhu, Sukhpal, Shah, Rohan, Sikorski, Bartosz, Sisk, Robert, Spinak, David-J., Stoltz, Robert, Takayama, Kei, Taleb, Alexandre, Talks, James, Tuli, Raman, Lith-Verhoeven, Janneke Van, Wells, John A., Wickremasinghe, Sanjeewa, Williams, Geoff, Williams, Thomas, Wong, James, Wong, Robert, Yasuda, Kanako, Yoon, Young Hee, Yu, Hyeong Gon

“…To evaluate 2-year efficacy, durability, and safety of the bispecific antibody faricimab, which inhibits both angiopoietin-2 and VEGF-A. TENAYA…”
Get full text

Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration by Holekamp, Nancy, Wykoff, Charles C., Schmitz-Valckenberg, Steffen, Monés, Jordi, Souied, Eric H., Lin, Hugh, Rabena, Melvin D., Cantrell, Ronald A., Henry, Erin C., Tang, Fan, Swaminathan, Balakumar, Martin, Jillian, Ferrara, Daniela, Staurenghi, Giovanni

“…To better characterize visual function decline and geographic atrophy (GA) progression secondary to age-related macular degeneration (AMD). Proxima A…”
Get full text

YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale by Eter, Nicole, Singh, Rishi P, Abreu, Francis, Asik, Kemal, Basu, Karen, Baumal, Caroline, Chang, Andrew, Csaky, Karl G, Haskova, Zdenka, Lin, Hugh, Ruiz, Carlos Quezada, Ruamviboonsuk, Paisan, Silverman, David, Wykoff, Charles C, Willis, Jeffrey R

“…PurposeFaricimab is a novel anti-angiopoietin-2 and anti-vascular endothelial growth factor (VEGF) bispecific antibody with high affinities and specificities…”
Get full text

TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration by Khanani, Arshad M, Guymer, Robyn H, Basu, Karen, Boston, Heather, Heier, Jeffrey S, Korobelnik, Jean-François, Kotecha, Aachal, Lin, Hugh, Silverman, David, Swaminathan, Balakumar, Willis, Jeffrey R, Yoon, Young Hee, Quezada-Ruiz, Carlos

“…PurposeTo describe the design and rationale of the phase 3 TENAYA (ClinicalTrials.gov identifier, NCT03823287) and LUCERNE (ClinicalTrials.gov identifier,…”
Get full text

TENAYA and LUCERNE: 2-Year Results from the Phase 3 nAMD Trials of Faricimab with Treat-and-Extend Dosing in Year 2 by Khanani, Arshad M, Kotecha, Aachal, Chang, Andrew, Chen, Shih-Jen, Chen, Youxin, Guymer, Robyn, Heier, Jeffrey S, Holz, Frank G, Iida, Tomohiro, Ives, Jane A, Lim, Jennifer I, Lin, Hugh, Michels, Stephan, Quezada Ruiz, Carlos, Schmidt-Erfurth, Ursula, Silverman, David, Singh, Rishi, Swaminathan, Balakumar, Willis, Jeffrey R, Tadayoni, Ramin

“…To evaluate the 2-year efficacy, durability, and safety of the bispecific antibody, faricimab, which inhibits both angiopoietin-2 and vascular endothelial…”
Get full text

Management of post-LASIK dry eye: a multicenter randomized comparison of a new multi-ingredient artificial tear to carboxymethylcellulose by Wallerstein, Avi, Jackson, W Bruce, Chambers, Jeffrey, Moezzi, Amir M, Lin, Hugh, Simmons, Peter A

“…To compare the efficacy and safety of a preservative-free, multi-ingredient formulation of carboxymethylcellulose 0.5%, hyaluronic acid 0.1%, and organic…”
Get full text

Axial Length Does Not Correlate With Degree of Visual Field Loss in Myopic Chinese Individuals With Glaucomatous Appearing Optic Nerves by Chao, Daniel Lee, Shrivastava, Anurag, Kim, Donna H, Lin, Hugh, Singh, Kuldev

“…PURPOSEWe previously described a group of patients of Chinese ancestry who presented with optic nerve appearance and visual field loss suggestive of glaucoma…”
Get full text